Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI

Phase 1

Completed

• Conditions: Leukemia; Leukemia, Myeloid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Hematologic Diseases
• Interventions: Drug: Radotinib

• Registration Number: NCT01602952
• Lead Sponsor: Il-Yang Pharm. Co., Ltd.

Brief Summary

A Phase I/II multicenter study of IY5511HCl in Philadelphia chromosome positive chronic myeloid leukemia patients without optimal response or tolerance to Bcr-Abl tyrosine kinase inhibitors (Imatinib and/ or Dasatinib, Nilotinib) In this study, The efficacy and safety of CML patients who are resistant or intolerable to imatinib in the Chronic and Accelerated phases.

Phase 1

1. To investigate the Maximum Tolerated Dose (MTD) and the Dose Limiting Toxicity (DLT) of oral Radotinib HCl bid (twice daily) in the Philadelphia chromosome-positive CML subjects who are resistant, suboptimal responsive, or intolerant to imatinib OR resistant or intolerant to at least one second-generation targeted anticancer agent while being resistant, suboptimal responsive, or intolerant to imatinib simultaneously.

Phase 2

1. To investigate safety of oral Radotinib HCl in CML patients who are resistant or intolerable to imatinib in the chronic and accelerated phases.

2. To evaluate hematologic and cytogenetic efficacy of oral Radotinib HCl in CML patients who are resistant or intolerable to imatinib in the chronic and accelerated phases.

Detailed Description

This study is a multi-center, open-label, Phase 1/2 clinical trial of Radotinib HCl, a targeted anticancer agent that inhibits the Bcr-Abl oncoprotein. It is aimed at determining the optimal therapeutic dose and confirming safety and efficacy of Radotinib HCl. Phase 1 study began at St. Mary's hospital in Korea and Phase 2 study is ongoing at 9 Korean sites and about 7 sites in China, India and Thailand will take part in Phase 2. After determination of a safe and proper therapeutic dose in Phase 1, Phase 2 began continuously to evaluate efficacy in chronic and accelerated phases. Before the start of the Phase 2 trial, interim or final reports for the Phase 1 trial were reviewed by the Korean Food and Drug Administration.

Study Timeline

• Study Start: 2008-07
• Study First Submitted: 2012-04-20
• Study First Submitted QC: 2012-05-17
• Study First Posted: 2012-05-21
• Primary Completion: 2012-10
• Study Completion: 2018-07-13
• Status Verified: 2018-08
• Last Update Submitted: 2018-08-27
• Last Update Posted: 2018-08-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 85

Inclusion Criteria

Phase I

1. Age ≥ 18 years old
2. Ph+ CML patients who are resistant at chronic, accelerate, and acute phase, or suboptimal responsive, or intolerant to imatinib or resistant or intolerant to at least one second-generation targeted anticancer agent while being resistant, suboptimal responsive, or intolerant to imatinib simultaneously.
3. WHO Performance status of ≤2
4. Patients must have the following laboratory values With normal liver and renal function
5. Patients who have received interferon, other anti cancer drug or radiotherapy > 1 week prior to starting study drug.

Phase II

1. Age ≥ 18 years old
2. Ph+ CML patients in chronic or accelerated phase who are resistant or intolerant to Imatinib mesylate
3. WHO Performance status of ≤2
4. Patients must have the following laboratory values With normal liver and renal function
5. Patients who have received interferon, other anti cancer drug or radiotherapy > 1 week prior to starting study drug.

Exclusion Criteria

Phase I

1. CNS infiltration

2. Impaired cardiac function, including any one of the followings.

   • LVEF <45% as determined by MUGA scan or echocardiogram
   • Clinically significant resting bradycardia

3. Severe GI disease that may cause drug absorption problem of study drug

4. Use of therapeutic Warfarin

5. Acute or chronic liver or renal disease

6. Other concurrent severe and/or uncontrolled medical conditions

7. Treatment with any hematopoietic colony-stimulating growth factors ≤1 week prior to starting study drug.

8. Patients who are currently receiving treatment with medications have the potential to prolong the QT interval

9. Patients who have received Imatinib, interferon, other anti cancer drug or chemotherapy ≤ 1 week

10. Patients who have received Nilotinib and Dasatinib ≤4 weeks prior to starting study drug.

11. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy

12. Patients who are pregnant or breast-feeding or adults of reproductive potential not employing an effective method of birth control.

13. Patients not to agree using birth control during the study and for up 3 months following study completion.

14. HIV infection

Phase II

1. Blast phase CML

2. CNS infiltration

3. Impaired cardiac function, including any one of the following

   • LVEF< 45% as determined by MUGA scan or echocardiogram
   • Use of Cardiac pacemaker
   • ST depression > 1mm in 2 or more leads and/or T wave inversions in 2 or more contiguous leads
   • Congenital long QT syndrome
   • History of, or presence of significant ventricular or atrial tachyarrhythmias
   • Clinically significant resting bradycardia
   • QTcF> 480 msec on screening ECG
   • Right bundle branch block + left anterior hemiblock, Bifascicular block
   • Angina pectoris

4. Severe GI disease that may cause drug absorption problem of study

5. Use of therapeutic Warfarin

6. Acute or chronic liver or renal disease

7. Other concurrent severe and/or uncontrolled medical conditions

8. Treatment with any hematopoietic colony-stimulating growth factors ≤1 week prior to starting study drug.

9. Patients who are currently receiving treatment with medications have the potential to prolong the QT interval

10. Patients who have received Imatinib, interferon, other anti cancer drug or chemotherapy ≤ 1 week

11. Patients who have received wide field radiotherapy ≤4 weeks prior to starting study drug.

12. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy

13. Patients who are pregnant or breast-feeding or adults of reproductive potential not employing an effective method of birth control

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Radotinib	Radotinib	Phase 1 : 200mg/kg or 1200mg/m\^2 Phase 2 : 400mg Bid

Primary Outcome Measures

Name	Time	Method
Rate of Complete hematologic response(CHR)(Phase 2)	12 months	Main parameters for response assessment in the chronic and accelerated phases include Major Hematologic Responses (MR; No Evidence of Leukemia or NEL + Complete Hematologic Response or CHR) lasting for 4 weeks and at least one major cytogenetic response (MCyR)
To investigate the Maximum Tolerated Dose(Phase 1)	12 month	Radotinib will be given orally twice daily. Dose will be increased until it reaches MTD or the blood concentration of Radotinib stops rising

Secondary Outcome Measures

Name	Time	Method
To investigate the Dose Limiting Toxicity(Phase 1)	12 months	The initial cohort will include 3 subjects who will receive 100mg Radotinib daily. If DLT is observed in one of the 3 subjects, the same dose will be given to 3 more subjects to evaluate safety.
Rate of complete Cytogenetic Response(CCyR)(Phase 2)	12 months	Cytogenetic response rate will be calculated as the percentage of Ph+ bone marrow metaphases as follows at least 20 bone marrow metaphases should be analyzed.
Adverse events(Phase 1& Phase 2)	12 months	All adverse events recorded during the study will be itemized and summarized. Severity, relation to the study medication, and seriousness will be summarized for each adverse event.
Progression-free survival or PFS	12 months	It is defined as the duration from the first day of administration to the earliest day of disease progression or death for certain causes. In subjects who have shown response, disease progression is defined as loss of MCyR.

Trial Locations

Locations (2)

Seoul St. Mary's hospital; 🇰🇷 Seoul, Seocho-gu, Korea, Republic of

Local institution; 🇹🇭 Bangkok, Phyathai, Thailand